Black Rock Coffee Bar, Inc. Class A BRCB 深 滬
已收盤 05-22 16:00:00 美东时间
6.81
+0.230
+3.50%
華盛通- 最 高7.105
- 今 開6.74
- 成交量 109.91万股
- 最 低 6.66
- 昨 收 6.58
- 總市值 3.41亿
- 52周最高 30.40
- 市盈率 靜 --
- 換手率 2.20%
- 52周最低 6.13
- 委 比 -76.05%
- 總股本 5005.58万
- 歷史最高 30.40
- 量 比 1.09
- 振 幅 6.76%
- 歷史最低 6.13
- 每 手 1
- 風險率 5.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多The High-Yield Stocks the Smart Money Is Buying Right Now
Smart credit team Ares Mgmt bought discounted BDCs aggressively in Q1 2026. They're not guessing but expressing conviction in 17 positions.
今天 01:33
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
Gainers Robo.ai (NASDAQ:AIIO) shares rose 65.2% to $2.12 during Wednesday's re...
05-14 01:06
Black Rock Coffee Bar Q1 2026 Earnings Call Transcript
Black Rock Coffee Bar (NASDAQ:BRCB) reported first-quarter financial results on...
05-13 06:36
Black Rock Coffee Bar Q1 EPS $0.02 Misses $0.03 Estimate, Sales $55.500M Miss $56.651M Estimate
Black Rock Coffee Bar (NASDAQ:BRCB) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. The company reported quarterly sales of $55.500 million which
05-13 04:08
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
DA Davidson Maintains Buy on Black Rock Coffee Bar, Lowers Price Target to $16
DA Davidson analyst Matt Curtis maintains Black Rock Coffee Bar (NASDAQ:BRCB) with a Buy and lowers the price target from $21 to $16.
05-06 02:03
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Raymond James Maintains Outperform on Black Rock Coffee Bar, Lowers Price Target to $20
Raymond James analyst Brian Vaccaro maintains Black Rock Coffee Bar (NASDAQ:BRCB) with a Outperform and lowers the price target from $22 to $20.
04-21 20:04
